Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biodexa Pharmaceuticals PLC BDRX

Healthcare Biotechnology
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing... see more

Recent & Breaking News (NDAQ:BDRX)

Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)

GlobeNewswire September 21, 2023

Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites

GlobeNewswire July 28, 2023

Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement

GlobeNewswire July 24, 2023

Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)

GlobeNewswire July 10, 2023

Results of Appeal of Delisting Determination

GlobeNewswire July 6, 2023

Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)

GlobeNewswire July 6, 2023

ADR Ratio Change

GlobeNewswire June 22, 2023

Appeal of Delisting Determination

GlobeNewswire June 20, 2023

Receipt of NASDAQ Delisting Determination Plans to Appeal

GlobeNewswire June 15, 2023

Results of Annual General Meeting and General Meeting

GlobeNewswire June 14, 2023

Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering

GlobeNewswire May 26, 2023

Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering

GlobeNewswire May 24, 2023

Posting of Annual Report & Notice of AGM

GlobeNewswire May 22, 2023

Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals

GlobeNewswire May 18, 2023

Preliminary Results for the Year Ended 31 December 2022

GlobeNewswire April 28, 2023

Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity

Accesswire April 20, 2023

Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity

Accesswire April 11, 2023

Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity

Accesswire April 6, 2023

Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity

Accesswire April 5, 2023

Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity

Accesswire April 4, 2023